PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 16 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

12 March 2026

  1. (diff | hist) 04:24 VendorInvestigate 5,067 ±0 PrepHPLC_Pia (talk | contribs) give the fields a compendially-complete certificate would carry [rollback]

11 March 2026

  1. (diff | hist) m 21:46 PolyPeptide Group (Hangzhou) 17,868 +220 GIP_Genoveva (talk | contribs) ce per PP:MOS [rollback]
  2. (diff | hist) 17:36 TRIUMPH trial programme 4,703 ±0 DMF_Dermot (talk | contribs) add the randomisation ratio [rollback]
  3. (diff | hist) m 17:23 STEP trial programme 5,534 ±0 BatchNumberBede (talk | contribs) add the trial acronym expansion at first use [rollback]
  4. (diff | hist) 17:04 Retatrutide 7,421 ±0 SelectTrialSam (talk | contribs) split §Pharmacology into receptor binding and downstream signalling [rollback]
  5. (diff | hist) 14:30 Talk:Amylin 611 +173 BetaCellBoyd (talk | contribs) /* Amyloid: cause or consequence? */ reply
  6. (diff | hist) 13:55 Talk:Sterile water for injection 611 +106 BacWaterBarnaby (talk | contribs) /* Sterility does not transfer */ reply
  7. (diff | hist) 13:25 Talk:Baseline laboratory panel 611 +87 NPOV_Nadia (talk | contribs) /* Table is not a recommendation */ reply
  8. (diff | hist) 10:20 Talk:Sterile water for injection 400 +175 EndotoxinEd (talk | contribs) /* Sterility does not transfer */ new section
  9. (diff | hist) 10:15 Talk:Amylin 400 +215 AmylinAmos (talk | contribs) /* Amyloid: cause or consequence? */ new section
  10. (diff | hist) 09:50 Talk:Baseline laboratory panel 400 +151 PanelPlannerPam (talk | contribs) /* Table is not a recommendation */ new section
  11. (diff | hist) 09:38 Talk:Temperature excursion 1,233 +228 StabilityStig (talk | contribs) /* Should freezing be a separate article? */ reply
  12. (diff | hist) 05:48 Preparative HPLC purification 4,882 ±0 ResinRhoswen (talk | contribs) correct the eutectic temperature — source gives a range [rollback]
  13. (diff | hist) 04:40 SinoPep 18,140 ±0 FreightFenna (talk | contribs) attribute the documentation description to the purchaser reports it comes from [rollback]
  14. (diff | hist) m 02:36 Peptide harm reduction 4,800 ±0 TierTwoTansy (talk | contribs) add the harm-reduction cross-link [rollback]
  15. (diff | hist) 02:25 Underfilling 4,882 ±0 CoI_Corin (talk | contribs) rm the inference from one report to a supplier [rollback]
  16. (diff | hist) 01:20 Lyophilisation 28,679 ±0 Chromatokid (talk | contribs) ce per PP:MOS [rollback]
  17. (diff | hist) 00:39 Dipeptidyl peptidase-4 7,022 ±0 EscalationEira (talk | contribs) give the magnitude of the incretin effect as a percentage of the insulin response [rollback]

10 March 2026

  1. (diff | hist) 22:35 Trifluoroacetate counterion 5,116 ±0 Peptide_Pete (talk | contribs) expand §Determination [rollback]
  2. (diff | hist) 16:04 Talk:Temperature excursion 1,022 +340 ColdChainCleo (talk | contribs) /* Should freezing be a separate article? */ reply
  3. (diff | hist) 14:45 GLP-1 receptor agonist 11,264 ±0 TimelineTiernan (talk | contribs) sentence case in headings per PP:MOS [rollback]
  4. (diff | hist) 13:26 Talk:Temperature excursion 811 +352 MergeMorwenna (talk | contribs) /* Should freezing be a separate article? */ new section
  5. (diff | hist) 13:20 Talk:Prescribing information 611 +108 ClinicCorrespondent (talk | contribs) /* Warnings versus contraindications */ reply
  6. (diff | hist) 10:30 Active pharmaceutical ingredient 4,569 ±0 Compounding_Cate (talk | contribs) typo [rollback]
  7. (diff | hist) 10:07 Cold-chain freight 4,758 ±0 RepackRadek (talk | contribs) expand §How much it matters for a lyophilised peptide [rollback]
  8. (diff | hist) 09:45 Talk:Prescribing information 400 +128 LabelLibby (talk | contribs) /* Warnings versus contraindications */ new section
  9. (diff | hist) m 02:41 Body composition assessment 5,029 ±0 PlainNumbersPip (talk | contribs) add the body-composition measurement method to the comparison [rollback]
  10. (diff | hist) 01:59 Good manufacturing practice 5,123 ±0 CheckSumChase (talk | contribs) expand §What GMP requires [rollback]
  11. (diff | hist) 01:53 Global access disparity 4,391 ±0 SemaglutideSasha (talk | contribs) add the equity point with the study that measured it [rollback]

9 March 2026

  1. (diff | hist) 13:55 Talk:Medutest 611 +193 Chromatokid (talk | contribs) /* Comparability table */ reply
  2. (diff | hist) 13:15 Talk:Placebo-adjusted effect 611 +130 ForestPlotFinn (talk | contribs) /* Placebo response is only one component */ reply
  3. (diff | hist) m 13:00 Incretin effect 7,358 ±0 EndpointEnid (talk | contribs) add see also to the sister hormone [rollback]
  4. (diff | hist) m 12:17 Mass spectrometry 5,612 ±0 GlossaryGleb (talk | contribs) add the repeatability figure with the number of injections [rollback]
  5. (diff | hist) m b 11:26 Nantong Guangyuan Chemical 15,114 ±0 CategoryBot (talk | contribs) bot: normalise citation format [rollback]
  6. (diff | hist) 10:20 Talk:Medutest 400 +80 SigFigSindri (talk | contribs) /* Comparability table */ new section
  7. (diff | hist) 09:40 Talk:Placebo-adjusted effect 400 +201 EndpointEnid (talk | contribs) /* Placebo response is only one component */ new section
  8. (diff | hist) 08:19 GenScript Peptides 17,125 +642 MolarMassMaeve (talk | contribs) add the note that self-published material is usable only for what it states about itself [rollback]
  9. (diff | hist) 08:15 Talk:Glucagon-like peptide-1 959 +77 Ref_Desk_Ron (talk | contribs) /* Readability of the signalling section */ reply

8 March 2026

  1. (diff | hist) 22:44 Number needed to treat 4,718 ±0 eGFR_Esme (talk | contribs) add the trial registration identifier [rollback]
  2. (diff | hist) 14:52 Talk:Glucagon-like peptide-1 748 +229 ReceptorRhoda (talk | contribs) /* Readability of the signalling section */ reply
  3. (diff | hist) 14:47 Talk:Beta cell function 748 +177 BetaCellBoyd (talk | contribs) /* The word "restores" */ reply
  4. (diff | hist) 13:50 Talk:Preparative HPLC purification 611 +138 Chromatokid (talk | contribs) /* Orthogonality argument */ reply
  5. (diff | hist) 11:20 Talk:Beta cell function 537 +179 PuffRemoverPax (talk | contribs) /* The word "restores" */ new section
  6. (diff | hist) m 10:56 Repackaging 4,759 ±0 UnitsUrsula (talk | contribs) state the residual-moisture target with the method it is measured by [rollback]
  7. (diff | hist) 10:44 Talk:Sigma-Aldrich (Shanghai) Trading 1,170 +117 NPOV_Nadia (talk | contribs) /* Trading company or synthesis house, and whether the article should say */ reply
  8. (diff | hist) 10:31 Talk:Glucagon-like peptide-1 537 +443 Ref_Desk_Ron (talk | contribs) /* Readability of the signalling section */ new section
  9. (diff | hist) 10:15 Talk:Preparative HPLC purification 400 +201 PrepHPLC_Pia (talk | contribs) /* Orthogonality argument */ new section
  10. (diff | hist) 09:18 Personal importation policy 4,121 ±0 ManualOfStyleMo (talk | contribs) add the customs-detention point with its source [rollback]
  11. (diff | hist) 06:35 Beta cell function 6,096 ±0 EmptyingElke (talk | contribs) alphabetise the see-also list [rollback]

7 March 2026

  1. (diff | hist) m 19:31 ISO 9001 4,278 ±0 BiosimilarBoaz (talk | contribs) state that research-use-only labelling is a commercial category, not an approval [rollback]
  2. (diff | hist) 19:18 Area percent purity 8,537 ±0 TFA_Counterion (talk | contribs) add the ionisation mode to the mass-spectrometry description [rollback]
  3. (diff | hist) m 12:41 Subcutaneous injection 5,293 ±0 UnitAuditUwe (talk | contribs) fix the arithmetic in the worked reconstitution example [rollback]
  4. (diff | hist) m 09:40 Janoshik Analytical 5,235 ±0 BatchNumberBede (talk | contribs) give the fields a compendially-complete certificate would carry [rollback]
  5. (diff | hist) 06:52 Insulin secretion 6,940 ±0 SatietySunniva (talk | contribs) add category for receptor pharmacology [rollback]
  6. (diff | hist) 03:33 AmbioPharm 15,052 ±0 ColumnOvenCoy (talk | contribs) state the city and province of the registered address [rollback]

6 March 2026

  1. (diff | hist) m 22:58 Sterile water for injection 4,738 ±0 SurpassSunniva (talk | contribs) add the beyond-use interval with the storage condition it assumes [rollback]
  2. (diff | hist) m 21:54 SELECT trial 5,171 ±0 SurmountSurma (talk | contribs) the trial was open-label; the article implied blinding [rollback]
  3. (diff | hist) m b 19:59 Semaglutide 10,355 ±0 CategoryBot (talk | contribs) bot: normalise citation format [rollback]
  4. (diff | hist) m 16:10 List of GLP-1 receptor agonists 3,862 ±0 RedirectRini (talk | contribs) expand the comparison so all four subjects have the same rows [rollback]
  5. (diff | hist) 14:15 Talk:Peptide 748 +130 CrossRefCleve (talk | contribs) /* GLP-1 numbering */ reply
  6. (diff | hist) 13:30 Talk:Injection site rotation 611 +168 SubQ_Solveig (talk | contribs) /* Applicability to weekly dosing */ reply
  7. (diff | hist) 11:37 Talk:Sigma-Aldrich (Shanghai) Trading 959 +257 COA_Colwyn (talk | contribs) /* Trading company or synthesis house, and whether the article should say */ reply
  8. (diff | hist) 10:50 Talk:Peptide 537 +198 CuriousCallum (talk | contribs) /* GLP-1 numbering */ new section
  9. (diff | hist) 09:55 Talk:Injection site rotation 400 +203 RotationRosalind (talk | contribs) /* Applicability to weekly dosing */ new section
  10. (diff | hist) 09:30 Talk:Dipeptidyl peptidase-4 822 +119 DPP4_Dagmar (talk | contribs) /* Is GLP-1(9-36) inert or not? */ reply
  11. (diff | hist) 08:29 Oral semaglutide 4,582 ±0 DrTitration (talk | contribs) state which salt form the mass in the infobox refers to [rollback]
  12. (diff | hist) 03:39 Sterility testing 4,776 ±0 IncretinIvo (talk | contribs) add the counterion determination method by name [rollback]
  13. (diff | hist) m 02:21 Shanghai Wibson Biotechnology 15,440 ±0 StubTagTeodor (talk | contribs) rm the adjective — an organisation article describes, it does not praise [rollback]

5 March 2026

  1. (diff | hist) m 20:48 Sangon Biotech 14,764 ±0 COA_Colwyn (talk | contribs) add the storage and handling guidance the organisation publishes [rollback]
  2. (diff | hist) m 17:27 Test report forgery 5,391 ±0 IncretinIvo (talk | contribs) clarify that a signature on a certificate is a release, not a verification [rollback]
  3. (diff | hist) 16:17 Qingdao Sigma Chemical 15,455 ±0 COA_Colwyn (talk | contribs) correct the other-designations row — those are trading variants, not subsidiaries [rollback]
  4. (diff | hist) m b 14:22 Certificate of analysis 10,014 ±0 StubSorterBot (talk | contribs) bot: sort category members [rollback]
  5. (diff | hist) m 13:42 Baseline laboratory panel 4,429 ±0 FerritinFay (talk | contribs) add the standardisation programme the assay is traceable to [rollback]
  6. (diff | hist) 13:32 Drug master file 4,325 ±0 QuietQuill (talk | contribs) correct the agency abbreviation at first use [rollback]
  7. (diff | hist) 13:15 Talk:Cagrilintide 611 +105 AmylinAmos (talk | contribs) /* Calcitonin receptor engagement */ reply
  8. (diff | hist) 13:10 Talk:Trifluoroacetate counterion 611 +130 PlainNumbersPip (talk | contribs) /* The worked arithmetic */ reply
  9. (diff | hist) m 13:04 Glucagon 7,074 ±0 CommaCarys (talk | contribs) clarify that the peptide backbone is acylated rather than PEGylated [rollback]
  10. (diff | hist) 12:19 Talk:Dipeptidyl peptidase-4 611 +180 ReceptorRhoda (talk | contribs) /* Is GLP-1(9-36) inert or not? */ reply
  11. (diff | hist) 10:40 Talk:Lyophilisation 1,581 +95 Ref_Desk_Ron (talk | contribs) /* Worked sublimation example: single vial or batch? */ reply
  12. (diff | hist) 09:40 Talk:Cagrilintide 400 +154 CagriCass (talk | contribs) /* Calcitonin receptor engagement */ new section
  13. (diff | hist) 09:35 Talk:Trifluoroacetate counterion 400 +135 TFA_Counterion (talk | contribs) /* The worked arithmetic */ new section
  14. (diff | hist) 08:44 Talk:Dipeptidyl peptidase-4 400 +261 DPP4_Dagmar (talk | contribs) /* Is GLP-1(9-36) inert or not? */ new section
  15. (diff | hist) 04:36 Insulin syringe 4,944 ±0 StubTagTeodor (talk | contribs) add category for preparation and handling [rollback]
  16. (diff | hist) 01:40 Customs seizure 4,785 ±0 GastroparesisGwen (talk | contribs) add category for drug regulation [rollback]

4 March 2026

  1. (diff | hist) 14:00 Talk:Counterfeit peptide 611 +172 SPPS_Sorrel (talk | contribs) /* Deletion sequence is not a counterfeit */ reply
  2. (diff | hist) 13:25 Talk:Hypoglycaemia 611 +96 BetaCellBoyd (talk | contribs) /* Mechanistic argument is not a guarantee */ reply
  3. (diff | hist) 13:25 Talk:List of GLP-1 receptor agonists 611 +80 DPP4_Dagmar (talk | contribs) /* Excluding DPP-4 inhibitors */ reply
  4. (diff | hist) 13:13 Albumin binding half-life extension 6,399 ±0 GIP_Genoveva (talk | contribs) distinguish the active and total forms of the hormone throughout [rollback]
  5. (diff | hist) 13:02 Talk:Sigma-Aldrich (Shanghai) Trading 748 +211 PrimarySrcPatia (talk | contribs) /* Trading company or synthesis house, and whether the article should say */ reply
  6. (diff | hist) m b 12:39 Grey market 4,279 ±0 CiteBot (talk | contribs) bot: normalise unit spacing [rollback]
  7. (diff | hist) 10:58 Purity claim inflation 5,660 ±0 PurityClaimPia (talk | contribs) expand §Reading against inflation [rollback]
  8. (diff | hist) 10:36 Peptide synthesis 5,649 ±0 CustomsClarke (talk | contribs) the article confused primary and secondary drying; corrected [rollback]
  9. (diff | hist) 10:20 Talk:Counterfeit peptide 400 +173 CounterfeitCato (talk | contribs) /* Deletion sequence is not a counterfeit */ new section
  10. (diff | hist) 09:50 Talk:Hypoglycaemia 400 +119 HypoHildur (talk | contribs) /* Mechanistic argument is not a guarantee */ new section
  11. (diff | hist) 09:50 Talk:List of GLP-1 receptor agonists 400 +147 ListMakerLumi (talk | contribs) /* Excluding DPP-4 inhibitors */ new section
  12. (diff | hist) 09:15 Talk:Sigma-Aldrich (Shanghai) Trading 537 +301 ScopeSeverin (talk | contribs) /* Trading company or synthesis house, and whether the article should say */ new section
  13. (diff | hist) m 03:50 Shenzhen Hybio Pharmaceutical 16,352 +226 BlankVialBo (talk | contribs) clarify that no manufacturing or marketing authorisation is claimed or established [rollback]
  14. (diff | hist) 03:49 Syringe dead space 20,340 +55 ForestPlotFinn (talk | contribs) ce [rollback]
  15. (diff | hist) 01:52 Peptide 6,813 ±0 PrepHPLC_Pia (talk | contribs) ce, tighten prose [rollback]

3 March 2026

  1. (diff | hist) m 22:36 Placebo-adjusted effect 4,805 ±0 StyleSheetSybil (talk | contribs) expand §How figures are misreported [rollback]